

Agile Therapeutics Company Presentation

April 2024



NASDAQ: AGRX

Forward-Looking Statements

Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla, including the increasing demand for Twirla in 2024, our partnership with Afaxys and its ability to promote growth, our product supply agreement with Nurx and its ability to educate patients about Twirla, our connected TV (CTV) campaign and its ability to promote growth, our prospects for future financing arrangements, and our financial condition, growth and strategies. Any or all of the forward- looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to raise additional capital, ability to pay our obligations as they become due, ability to maintain regulatory approval of Twirla and the labeling under any approval we obtain, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully enhance the commercialization of and increase the uptake for Twirla, the size and growth of the markets for Twirla and our ability to serve those markets, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla and our product candidates, clinical trials, supply chain, operations and the operations of third parties we rely on for services such as manufacturing, marketing support and sales support, as well as on our potential customer base, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.




NASDAQ: AGRX



Company & Product Overview

Who We Are

- Agile Therapeutics® is a commercial-stage women's healthcare company dedicated to fulfilling the unmet health needs of today's women
- Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options
- Currently focused on growth of our first FDA-approved product Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
- Headquartered in Princeton, NJ



Establish Agile in
Contraceptive Market
by Growing Twirla®

Become a
Contraceptive
Market Leader

Broaden Women's
Health Portfolio in
Areas of Unmet Need

Twirla® is the first and only birth control patch delivering a low dose of estrogen.¹⁻⁵

A LOWER ESTROGEN DOSE THAN OTHER CONTRACEPTIVE PATCHES


Twirla delivers 30 mcg of estrogen daily, **the lowest exposure of estrogen in a transdermal contraceptive option.**²⁻⁴



Not actual size.
For illustrative purposes only.

WOVEN, FLEXIBLE FABRIC

Only Twirla uses **Skinfusion® patch technology** for consistent drug delivery and to help maintain adhesion. Twirla is made with a soft, flexible fabric designed to contour with a woman's body.



DEMONSTRATED SAFETY PROFILE

In the SECURE Trial, conducted in a large and diverse group of women, **Twirla was found to be a safe and well-tolerated weekly option** in women with a BMI <30 kg/m² for whom a combined hormonal contraceptive is appropriate.^{1,2}

PURPOSEFULLY INCLUSIVE TRIAL

Efficacy and safety were established in a purposefully inclusive trial that featured a diverse study population, **closely representative of the demographics of women across the US.**¹


Twirla® is a weekly hormonal birth control patch for women with a body mass index (BMI) less than 30 kg/m² who can become pregnant. Twirla is less effective in women with a BMI of 25 kg/m² or more and should not be used in women whose BMI is 30 kg/m² or more.

References: 1. Nelson AL, Kaunitz AM, Kroll R, et al. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results. *Contraception*. 2021;103(3):137-143. 2. Twirla [prescribing information]. Princeton, NJ: Agile Therapeutics, Inc.; 2020. 3. Xulane [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; 2020. 4. Zafemy [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2021. 5. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Morb Mortal Wkly Rep*. 2016;65(3):1-104.

Twirla: Birth Control Designed to Fit Her Life


Weekly. Self-Administered. Just 3 Patches a Month.

THE DAILY PILL ROUTINE:




Stop and take it every day, ideally at the same time each day for at least 21 days each month.

WITH TWIRLA, SHE CHANGES THE PATCH JUST ONCE A WEEK FOR 3 WEEKS EACH MONTH




During the fourth week of the cycle, she wears no patch and should expect her period.

TWIRLA MAY BE APPLIED TO ONE OF THE FOLLOWING LOCATIONS ON THE SKIN




Twirla Performance Update

Year-Over-Year Net Revenue & OpEx Improvement



Twirla Quarterly Demand


Demand Rebound from Q4 2023 is Occurring*




Demand Rebound from Q4 2023 is Occurring*



Year-Over-Year Twirla Demand Improvement



Factory Sales (Cycles) and Managed OpEx



Twirla Business Plan: Potential For Further Upside

Twirla Business Plan Goal

- Capital-Efficient Business That Can Generate Sustainable Growth

Partnership Model

Retail Channel Growth Drivers



Twirla Sales Force



Telemedicine

NURX.

twentyeight

pandia
health



Specialty Pharmacy

phil

Carepoint[™]

Sterling
SPECIALTY PHARMACY

KnipperHEALTH
Creating the Path to Smarter Outcomes[™]

Non-Retail Channel Growth Drivers

afaxys[™]
affordable access[™]

Planned Parenthood[®]

MMCAP
INFUSE

Targeting “Big 5” States



- Agile continues to focus its Twirla promotional efforts on **five states** that have **high levels of reimbursement** potential for Twirla and are estimated to reach **over 45% of U.S. women between the ages of 18 and 24**
- This targeted geographical strategy ensures marketing spend maximizes greatest opportunity/potential

Retail Channel Growth Driver: Telemedicine

The Nurx logo features the word "NURX." in a bold, black, sans-serif font. It is centered within a circular graphic composed of two concentric arcs: an outer white arc and an inner magenta arc. The logo is set against a light blue background within a rounded rectangular frame.

- Collaboration with female telemedicine leader Nurx will make **Twirla an available option to Nurx patients.**
- Nurx medical providers have prescribed contraception to **more than 1 million patients.**
- **Shared marketing initiative designed to raise Twirla awareness** among Nurx's large contraceptive patient network.
- Full launch of Nurx collaboration occurred in fourth quarter 2022 and **impact on the retail channel expected to be realized in 2024.**

Non-Retail Channel Growth Driver: Afaxys Partnership



- **Non-retail demand grew 330% (22,533 to 96,843 total cycles) in 2023 compared to 2022.**
- **Growth driven by Afaxys-led promotion to the Planned Parenthood network.**
- Recent performance includes **conversion of Planned Parenthood accounts in California.**
- The Company believes there is **additional potential for Twirla volume growth** in this channel based on the reach of the Afaxys customer network.

Potential Breakthrough for Access to Contraceptive Products like Twirla® Resolution Appears Prioritized and Imminent

